Rafferty Asset Management
CRVS icon

Rafferty Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Rafferty Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.65M Buy
112,608
+12,884
+13% +$206K 0.01% 650
2025
Q4 		$768K Buy
+99,724
New +$786K ﹤0.01% 838

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Rafferty Asset Management's CRVS Position: Q1 2026 in Review

Rafferty Asset Management increased its Corvus Pharmaceuticals (CRVS) stake by 13% in Q1 2026, buying an estimated $206K and bringing the position to 112,608 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #650.

Rafferty Asset Management first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Rafferty Asset Management held 112,608 shares of Corvus Pharmaceuticals worth $1.65M as of Q1 2026.
  • Rafferty Asset Management bought 12,884 Corvus Pharmaceuticals shares in Q1 2026, an estimated $206K.
  • Corvus Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #650 holding.
  • Rafferty Asset Management first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.